Last reviewed · How we verify
NCT03637361
Safety, Tolerability and Pharmacokinetics of Single Ascending Doses of REL-1017 (d-Methadone)
Phase 1 trial testing REL-1017 in Neuropathic Pain in 42 participants. Completed in 2 June 2015.
2 June 2015
Quick facts
| Lead sponsor | Relmada Therapeutics, Inc. |
|---|---|
| Phase | Phase 1 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | double |
| Primary purpose | basic science |
| Enrollment | 42 |
| Start date | 4 December 2014 |
| Primary completion | 2 June 2015 |
| Estimated completion | 2 June 2015 |
Drugs / interventions tested
- REL-1017 — full drug profile →
- Placebo
Conditions studied
- Neuropathic Pain — all drugs for Neuropathic Pain →
Sponsor
Relmada Therapeutics, Inc. — full company profile →
Who can join
Adults 18 to 55, any sex, with Neuropathic Pain. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study evaluated the safety, tolerance, and pharmacokinetics (PK) of d-methadone in a limited dose range, in single administrations in humans.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
REL-1017 (Esmethadone) Increases Circulating BDNF Levels in Healthy Subjects of a Phase 1 Clinical Study.
De Martin S, Gabbia D, Folli F, Bifari F, et al · · 2021 · cited 24× · PMID 33995104 · DOI 10.3389/fphar.2021.671859
Verify or expand the search:
- PubMed search for NCT03637361
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of REL-1017
Trials testing the same drug.
- NCT06011577 — Randomized, Double-Blind, Placebo-Controlled Trial of REL-1017 as Adjunctive Treatment for MDD · Phase 3 · terminated
- NCT05081167 — A Study to Assess the Efficacy and Safety of REL-1017 as Monotherapy for Major Depressive Disorder (MDD) · Phase 3 · completed
- NCT04855760 — Safety of REL-1017 for Major Depressive Disorder · Phase 3 · completed
- NCT04855747 — A Study to Assess the Efficacy and Safety of REL-1017 as Adjunctive Treatment for Major Depressive Disorder (MDD) · Phase 3 · terminated
- NCT04688164 — A Study to Assess the Efficacy and Safety of REL-1017 as Adjunctive Treatment for Major Depressive Disorder (MDD) · Phase 3 · completed
Other recruiting trials for Neuropathic Pain
Currently open trials in the same condition.
- NCT07493213 — USG-Guided Shoulder Injections in Frozen Shoulder · NA · recruiting
- NCT07493226 — Efficacy of Chemically Distinct Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) and Pain Phenotypes in Adhesive Capsulitis · NA · recruiting
- NCT06398847 — Virtual Reality (VR) Self-Hypnosis Software · NA · recruiting
- NCT07487610 — Relationship Between Neuropathic Pain and Geriatric Assessment Parameters in Patients Aged 80 Years and Older · recruiting
- NCT07436806 — SPS Block vs. Surgical Intercostal Block for Chronic Pain After Thoracoscopic Surgery · NA · recruiting
Other Relmada Therapeutics, Inc. trials
Trials by the same sponsor.
- NCT07342517 — A Study of NDV-01 as an Intravesical Administration to Patients With BCG-Unresponsive Non-Muscle Invasive Bladder Cancer · Phase 3 · withdrawn
- NCT07313891 — A Study of Adjuvant NDV-01 (Sustained-release Gemcitabine-docetaxel) for the Treatment of Intermediate Risk NMIBC Follow · Phase 3 · withdrawn
- NCT05081167 — A Study to Assess the Efficacy and Safety of REL-1017 as Monotherapy for Major Depressive Disorder (MDD) · Phase 3 · completed
- NCT04855760 — Safety of REL-1017 for Major Depressive Disorder · Phase 3 · completed
- NCT04688164 — A Study to Assess the Efficacy and Safety of REL-1017 as Adjunctive Treatment for Major Depressive Disorder (MDD) · Phase 3 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03637361 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Relmada Therapeutics, Inc.
- Last refreshed: 1 August 2019
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03637361.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing